Zenufa Laboratories Ltd.

Zenufa Laboratories Ltd. is a pharmaceutical company committed to delivering high-quality and affordable healthcare products, significantly impacting the healthcare landscape in various regions, including Africa, India, and Canada. Zenufa Laboratories Ltd. is based in Dar es Salaam, Tanzania, and was founded in 2005.

The company specializes in manufacturing pharmaceuticals and has been active since its inception, focusing on developing effective healthcare solutions. The CEO, Shyam Visani, leads the firm, which has a history of enhancing its product range to meet the dynamic needs of healthcare providers. In October 2016, Catalyst Principal Partners acquired a controlling stake in the company for an undisclosed amount. Zenufa has engaged in one investment deal to date.

Zenufa Group of Companies provides a diverse array of healthcare solutions, concentrating on affordable and quality pharmaceutical products. Their offerings include antibiotics, anti-infectives, and antimalarial medications, designed to address critical health needs. The company serves both public and private healthcare sectors across Africa, India, and Canada, ensuring accessibility for hospitals, clinics, and individual consumers, with a product portfolio that has evolved since its establishment in 1976 in the Democratic Republic of Congo. Zenufa Group generates revenue through direct sales of pharmaceuticals to healthcare providers and distributors.

The company operates a business-to-business model, supplying hospitals and pharmacies and establishing partnerships with various healthcare organizations. Transactions often involve bulk orders of flagship products, enabling the company to build long-term relationships with clients. Their pricing strategy focuses on affordability without compromising quality, which supports a steady revenue stream as they adapt to the healthcare industry's evolving demands. Zenufa Laboratories Ltd.

aims to introduce new pharmaceutical products designed to meet specific market needs, with plans for launches set around the upcoming years. The company is actively pursuing expansion opportunities into new geographic markets, specifically targeting regions in Africa and India by 2025. Recent funding from the acquisition in October 2016 will be utilized to support these initiatives, enhancing their product development and market penetration strategies.